Results 51 to 60 of about 1,038,668 (364)

JAK2 V617f in chronic myeloid leukemia: driving force or passive bystander?

Hematology, 2022
Objectives BCR-ABL1 and JAK2 V617F coexistence in myeloproliferative neoplasms has been described as concomitant or sequential events. Despite this, we present a unique case of chronic myeloid leukemia (CML) not referable to either of the known scenarios.
Francesco Tarantini, Cosimo Cumbo, Antonella Zagaria, Elisa Parciante, Luisa Anelli, Nicoletta Coccaro, Giuseppina Tota, Crescenzio Francesco Minervini, Immacolata Redavid, Antonella Russo Rossi, Maria Rosa Conserva, Giorgina Specchia, Pellegrino Musto, Francesco Albano   +13 more
doaj   +1 more source

Outcomes of Live Virus Vaccination in Patients With Vascular Anomalies Being Treated With Sirolimus

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Live vaccination in patients with vascular anomalies (VA) receiving sirolimus remains controversial due to immunosuppressive effects and theoretical risks. Procedure This single‐center retrospective study included patients with VA less than 4 years old at the start of sirolimus therapy who were incompletely vaccinated.
Svatava Merkle, Kiersten Ricci, Kelly Blache, Rebecca A. Marsh, Adrienne M. Hammill, Elissa Engel   +5 more
wiley   +1 more source

Digital PCR Assays for Precise Quantification of CD19-CAR-T Cells after Treatment with Axicabtagene Ciloleucel

Molecular Therapy: Methods & Clinical Development, 2020
Treatment with axicabtagene ciloleucel (Axi-cel) CD19-CAR-T (chimeric antigen receptor T) cells has been approved for refractory/relapsed diffuse large B cell lymphoma (DLBCL) and primary mediastinal large B cell lymphoma (PMBCL).
Boris Fehse, Anita Badbaran, Carolina Berger, Tanja Sonntag, Kristoffer Riecken, Maria Geffken, Nicolaus Kröger, Francis A. Ayuk   +7 more
doaj   +1 more source

B cells in transplantation [PDF]

The Journal of Heart and Lung Transplantation, 2016
B cell responses underlie the most vexing immunological barriers to organ transplantation. Much has been learned about the molecular mechanisms of B cell responses to antigen and new therapeutic agents that specifically target B cells or suppress their functions are available.
Esme I, Dijke, Jeffrey L, Platt, Paul, Blair, Menna R, Clatworthy, Jignesh K, Patel, A G, Kfoury, Marilia, Cascalho   +6 more
openaire   +2 more sources

Efficacy and Safety Analysis of Roxarestat in Regulating Renal Anemia in Patients on Maintenance Hemodialysis

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Objective To compare the efficacy and safety of roxarestat versus recombinant human erythropoietin (rhEPO) in the management of renal anemia in patients undergoing maintenance hemodialysis. Methods This was a prospective, open‐label, randomized controlled trial.
Lingling Chen, Junjie Zhu, Qiaonan Ge
wiley   +1 more source

Determining the Quantitative Principles of T Cell Response to Antigenic Disparity in Stem Cell Transplantation [PDF]

, 2018
Alloreactivity compromising clinical outcomes in stem cell transplantation is observed despite HLA matching of donors and recipients. This has its origin in the variation between the exomes of the two, which provides the basis for minor ...
AbdulRazzaq, Badar, Buck, Greg, Hall, Charles E., Hashmi, Shahrukh, Jameson-Lee, Max, Kennedy, Caleb, Koparde, Vishal, Manjili, Masoud H., Meier, Jeremy, Neale, Michael, Qayyum, Rehan, Reed, Jason, Roberts, Catherine, Salman, Ali, Serrano, Myrna, Spellman, Stephen R., Toor, Amir A., Wijesinghe, Dayanjan   +17 more
core   +1 more source

Effects of the Fluid Replacement Method During Online Hemodiafiltration on the Solute Removal Performance and Biocompatibility Using the Asymmetric Cellulose Triacetate Membrane

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Introduction Pre‐dilution online hemodiafiltration (Pre‐HDF) is predominantly used in Japan, whereas post‐dilution online HDF (Post‐HDF) is more common in Europe. An asymmetric cellulose triacetate (ATA) membrane may improve biocompatibility.
Kenji Sakurai, Yoshitaka Kurihara, Fumi Yamauchi, Hiromi Hosoya, Takeshi Saito   +4 more
wiley   +1 more source

Targeting autophagy increases the efficacy of proteasome inhibitor treatment in multiple myeloma by induction of apoptosis and activation of JNK

BMC Cancer, 2022
Background The therapeutic armamentarium in multiple myeloma has been significantly broadened by proteasome inhibitors, highly efficient means in controlling of multiple myeloma.
Azam Salimi, Kema Marlen Schroeder, Mirle Schemionek-Reinders, Margherita Vieri, Saskia Maletzke, Deniz Gezer, Behzad Kharabi Masouleh, Iris Appelmann   +7 more
doaj   +1 more source

Infection Control Practices for Vascular Access Management in Hemodialysis: Results From a Nationwide Survey of Japanese National University Hospitals

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Introduction Bloodstream infections due to repeated vascular access (VA) puncture and circuit connections remain major concerns in hemodialysis. Therefore, we examined current practices for glove, disinfectant, and personal protective equipment (PPE) use according to VA type in national university hospitals in Japan.
Aiko Yamada, Makoto Harada, Tadahiko Kikugawa, Takeshi Nakata, Koji Hashimoto, Tsuneo Konta, Yuji Kamijo   +6 more
wiley   +1 more source

Primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphomas: reappraisal of a provisional entity in the 2016 WHO classification of cutaneous lymphomas. [PDF]

, 2017
Primary cutaneous CD8-positive aggressive epidermotropic T-cell lymphoma is a rare and poorly characterized variant of cutaneous lymphoma still considered a provisional entity in the latest 2016 World Health Organization Classification of Cutaneous ...
Duvic, Madeleine, Girardi, Michael, Guitart, Joan, Ivan, Doina S, Junkins-Hopkins, Jacqueline, Kim, Ellen, Kim, Jinah, Kim, Youn H, Martinez-Escala, M Estela, Olsen, Elise A, Pincus, Laura B, Pulitzer, Melissa P, Rook, Alain H, Sable, Kimberly A, Samimi, Sara S, Selim, M Angelica, Subtil, Antonio, Tetzlaff, Michael T, Virmani, Pooja, Wood, Gary S   +19 more
core   +1 more source